Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following EACS 2021—Audio Recap

Source: Clinical Impact of New HIV Data From EACS 2021*
October 27-30, 2021; London, United Kingdom
Listen to expert insights from Tristan J. Barber, MA, MD, FRCP, on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.
Tristan J. Barber, MA, MD, FRCP
Released: November 30, 2021

In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:

  • First-line therapies
    • BIC/FTC/TAF in a test-and-treat model in IMEA 055 FAST
    • Week 144 data of ISL + DOR in treatment-naive patients from P011
  • Switch Strategies
    • Data on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS Cohort
  • Long-Acting Therapies
    • Efficacy and safety of LA CAB + RPV by BMI
    • Long-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trials
    • Patient satisfaction with LA CAB + RPV from the CARISEL study
    • Resistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patients
  • COVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWH

Information on this Educational Activity

Faculty

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP, has disclosed that he has received funds for research support from Roche; consulting fees from Gilead Sciences, MSD, Theratechnologies, and ViiV; fees for non-CME/CE services from Gilead Sciences, MSD, and ViiV; and other financial or material support from Gilead Sciences and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

Expert insight on treatment strategies for NASH in patients living with HIV, from Clinical Care Options (CCO)

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 10, 2022 Expired: January 9, 2023

From Clinical Care Options (CCO) and Dr. Jürgen K. Rockstroh and Dr. Giada Sebastiani: Recommended approach for screening and diagnosing NASH in patients with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 10, 2022 Expired: January 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings